On 20 August 2021, the Therapeutic Goods Administration (TGA), part of the Department of Health, granted provisional approval to GlaxoSmithKline (GSK).
India is headed towards the fourth wave of the coronavirus, which could cause irreparable damage to its
population and economy. It can only be stopped by public awareness, sacrifice and cooperation.
Share Via Email
| A+A A-
India and the world are facing a vaccine crunch since the second and third waves are rising faster than the inoculation rate.
The frightening truth is that we do not know.
We do not know why after over 13 crore recorded Covid-19 infections, 30 lakh deaths, nearly 700 million vaccine doses given worldwide, including in India, the waves of death and destruction keep coming, crashing on the rocks of fear and speculation, threatening to drown humanity in its worst nightmare.
TGA provisionally approves AstraZeneca s COVID-19 vaccine
Search jobs TGA provisionally approves AstraZeneca s COVID-19 vaccine
The Therapeutic Goods Administration (TGA) has granted provisional approval to AstraZeneca Pty Ltd for its COVID-19 vaccine, making it the second COVID-19 vaccine to receive regulatory approval in Australia.
COVID-19 Vaccine AstraZeneca is provisionally approved and included in the Australian Register of Therapeutic Goods (ARTG) for the active immunisation of individuals 18 years and older for the prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2. The use of this vaccine should be in accordance with official recommendations and given in two separate doses. TGA s regulatory approval allows the second dose to be administered from 4 to 12 weeks after the first. The Australian Technical Advisory Group on Immunisation has recommended that the interval between first and second dose is 12 weeks. However if this i
Date Time
Australia approves Pfizer COVID-19 vaccine
The Therapeutic Goods Administration (TGA) has granted provisional approval to Pfizer Australia Pty Ltd for its COVID-19 vaccine, COMIRNATY, making it the first COVID-19 vaccine to receive regulatory approval in Australia.
Following a thorough and independent review of Pfizer’s submission, the TGA has decided that this vaccine meets the high safety, efficacy and quality standards required for use in Australia.
COMIRNATY is provisionally approved and included in the Australian Register of Therapeutic Goods (ARTG) for active immunisation to prevent coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, in individuals 16 years of age and older.